CoChat

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer, an aggressive subtype with a poor prognosis, was compared with standard care (chemotherapy with or without bevacizumab) in an open-label, phase 3 trial, which showed significance regarding one of the two primary end points, objective response according to blinded independent central review (odds ratio for EC+mFOLFOX6 vs. standard care, 2.44; one-sided P<0.001). This result led to accelerated Food and Drug Administration approval of this investigational combination therapy for BRAF V600E–mutated metastatic colorectal cancer, including as first-line therapy. Data on progression-free survival (the second primary end point) and an updated interim analysis of overall survival are now available. Methods We randomly assigned patients with untreated BRAF V600E–mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care. The two primary end points were objective response (reported previously) and progression-free survival according to blinded independent central review in the EC+mFOLFOX6 group and the standard-care group. The key secondary end point was overall survival. Results Significantly longer progression-free survival was seen with EC+mFOLFOX6 than with standard care (median, 12.8 vs. 7.1 months; hazard ratio for progression or death, 0.53; 95% confidence interval [CI], 0.41 to 0.68; P<0.001). In an interim analysis, overall survival was significantly longer with EC+mFOLFOX6 than with standard care (median, 30.3 vs. 15.1 months; hazard ratio for death, 0.49; 95% CI, 0.38 to 0.63; P<0.001). The incidence of serious adverse events during treatment was 46.1% with EC+mFOLFOX6 and 38.9% with standard care. Safety profiles were consistent with those known for each agent. Conclusions This trial showed significantly longer progression-free survival and overall survival with first-line treatment with EC+mFOLFOX6 than with standard care among patients with BRAF V600E–mutated metastatic colorectal cancer. (Funded by Pfizer and others; BREAKWATER ClinicalTrials.gov number, NCT04607421 .)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2501912

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Analysis of Progression-Free Survival by Blinded Independent Central Review. Panel A shows Kaplan-–Meier estimates of progression-free survival in the EC, EC+mFOLFOX6 and SOC arms. Panel B shows a forest plot of the analyses in pre-specified subgroups in the EC+mFOLFOX6 and SOC arms. *Analyses of EC versus SOC and EC versus EC+mFOLFOX6 are descriptive. CIs are not adjusted for multiplicity and should not be mistaken for hypothesis tests. Following a protocol amendment, enrollment into the EC arm was discontinued prematurely. †Subgroup analyses are exploratory and descriptive in nature; CIs are not adjusted for multiplicity and should not be interpreted as hypothesis tests. CI, confidence interval; EC, encorafenib and cetuximab; EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU; HR, hazard ratio; SOC, standard of care.
Figure 1. Analysis of Progression-Free Survival by Blinded Independent Central Review. Panel A shows Kaplan-–Meier estimates of progression-free survival in the EC, EC+mFOLFOX6 and SOC arms. Panel B shows a forest plot of the analyses in pre-specified subgroups in the EC+mFOLFOX6 and SOC arms. *Analyses of EC versus SOC and EC versus EC+mFOLFOX6 are descriptive. CIs are not adjusted for multiplicity and should not be mistaken for hypothesis tests. Following a protocol amendment, enrollment into the EC arm was discontinued prematurely. †Subgroup analyses are exploratory and descriptive in nature; CIs are not adjusted for multiplicity and should not be interpreted as hypothesis tests. CI, confidence interval; EC, encorafenib and cetuximab; EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU; HR, hazard ratio; SOC, standard of care.CC BY-NC-ND · PubMed Central
Figure 2. Analysis of Overall Survival. Panel A shows Kaplan–Meier estimates of overall survival in the EC, EC+mFOLFOX6 and SOC. Panel B shows a forest plot of the analyses in pre-specified subgroups in the EC+mFOLFOX6 and SOC arms. Because the result of the interim analysis of overall survival was statistically significant, no further statistical test will be performed. *Analyses of EC versus SOC and EC versus EC+mFOLFOX6 are descriptive. CIs are not adjusted for multiplicity and should not be mistaken for hypothesis tests. Following a protocol amendment, enrollment into the EC arm was discontinued prematurely. †Subgroup analyses are exploratory and descriptive in nature; CIs are not adjusted for multiplicity and should not be interpreted as hypothesis tests. CI, confidence interval; EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU; HR, hazard ratio; SOC, standard of care.
Figure 2. Analysis of Overall Survival. Panel A shows Kaplan–Meier estimates of overall survival in the EC, EC+mFOLFOX6 and SOC. Panel B shows a forest plot of the analyses in pre-specified subgroups in the EC+mFOLFOX6 and SOC arms. Because the result of the interim analysis of overall survival was statistically significant, no further statistical test will be performed. *Analyses of EC versus SOC and EC versus EC+mFOLFOX6 are descriptive. CIs are not adjusted for multiplicity and should not be mistaken for hypothesis tests. Following a protocol amendment, enrollment into the EC arm was discontinued prematurely. †Subgroup analyses are exploratory and descriptive in nature; CIs are not adjusted for multiplicity and should not be interpreted as hypothesis tests. CI, confidence interval; EC+mFOLFOX6, encorafenib and cetuximab plus oxaliplatin, leucovorin and 5-FU; HR, hazard ratio; SOC, standard of care.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 174

Metadata

Authors
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., Morris, V. K., Wu, C., Usari, T., Laliberte, R., Dychter, S. S., Zhang, X., Tabernero, J., & Kopetz, S.
Affiliations
  • Vall d’Hebron Hospital Campus, Barcelona
  • National Cancer Center Hospital East (JP)
  • Peking University Cancer Hospital (CN)
  • Istituto Oncologico Veneto (IT)
  • University Hospitals Gasthuisberg Leuven, Leuven, Belgium
  • Vanderbilt University (US)
  • Asan Medical Center (KR)
  • Hammersmith Hospital (GB)
  • The University of Melbourne (AU)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Memorial Sloan Kettering Cancer Center (US)
  • University of Liverpool, Liverpool, United Kingdom
  • The University of Texas MD Anderson Cancer Center (US)
  • Mayo Clinic Hospital (US)
  • Pfizer, Milan
  • Pfizer (United States) (US)
  • Universitat de Vic - Universitat Central de Catalunya (ES)
Venue
New England Journal of Medicine
Published
2025-06-26
Volume
392
Issue
24
Pages
2425-2437
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4410875702
Cited by
166
References
20
Citations by year
2026: 125 · 2025: 41
FWCI
67.60
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
Funders
  • Pfizer, Inc.
  • Clinical Center (Core Grant P30 CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
cetuximab, mFOLFOX6, BRAF V600E mutation, metastatic colorectal cancer, first-line therapy, progression-free survival, overall survival, oxaliplatin, bevacizumab, targeted therapy, drug safety, serious adverse events, EGFR inhibition, BRAF inhibitor combination therapy
MeSH terms
Cetuximab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carbamates, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Sulfonamides, Colorectal Neoplasms, Treatment Outcome, Proto-Oncogene Proteins B-raf, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2501912
The paper
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., Morris, V. K., Wu, C., Usari, T., Laliberte, R., Dychter, S. S., Zhang, X., Tabernero, J., & Kopetz, S. (2025). Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2501912

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.